Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CEO Says Strength Of R&D Arm Made Glenmark Buck Spinoff Trend (India)

This article was originally published in PharmAsia News

Executive Summary

The CEO of Glenmark Pharmaceuticals says his Indian company decided to spin off its generics business rather than its research and development operations, as is the norm, because R&D is the core of its business. Glenn Saidanha said he felt the R&D work could not be sustained on its own and saw no reason to keep it independent. His Indian competitors tend to spin off R&D work in an attempt to increase their funds, but Saidanha said Glenmark already had strong assets providing it with returns before its products go on the market. He also said Glenmark is in the market for small acquisition deals to add to its vertical integration. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065882

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel